Putting Your Best Foot Forward: Why Podiatry is Crucial in Chemotherapy Care
Chemotherapy can save lives, but at what cost to the feet? New research reveals a startling gap in post-treatment care, leaving many cancer survivors struggling with debilitating nerve damage. But there's a potential solution that's being overlooked.
A recent study from the University of South Australia shines a light on the overlooked issue of lower limb care in chemotherapy patients. The research found that up to half of patients undergoing chemotherapy for colorectal cancer may be missing out on podiatry services, despite the high risk of developing Chemotherapy Induced Peripheral Neuropathy (CIPN).
CIPN is a serious condition that affects the nerves in the feet and legs, causing symptoms such as numbness, tingling, pain, and weakness. It is a common side effect of platinum-based chemotherapy drugs like Oxaliplatin, which is used in the treatment of colorectal cancer.
But here's where it gets controversial: while CIPN can have a permanent impact on foot health and mobility, the study found that only a small fraction of patients accessed podiatry services, even years after treatment.
The research team, led by podiatrist and PhD candidate Sindhrani Dars, analyzed data from 3292 colorectal cancer patients, most of whom received Oxaliplatin. The results were eye-opening: fewer than 20% of patients sought podiatric care, despite the high prevalence of CIPN.
"Neurotoxic chemotherapy can leave lasting damage, impacting balance, muscle strength, and overall quality of life," explains Dars. "CIPN symptoms can be so severe that patients may consider reducing or stopping their chemotherapy. This highlights the urgent need for comprehensive care strategies."
And this is the part most people miss: podiatrists are highly skilled in managing lower limb complications and are an essential part of the solution. They can help prevent and manage CIPN symptoms, reducing the risk of falls, ulcers, and amputations, and improving patients' overall well-being.
"Podiatry is a vital yet underutilized resource in cancer survivorship care," Dars emphasizes. "By integrating podiatry into routine oncology care and raising awareness among patients and clinicians, we can significantly improve the management of neuropathy-related foot complications."
The study also highlights the lack of evidence-based guidelines for CIPN management in Australia, and the absence of podiatry services in the published clinical pathway. This gap in care is concerning, given the high incidence of CIPN among chemotherapy patients.
To address this issue, the research team has developed clinical recommendations for the care and management of CIPN symptoms, available online. These guidelines aim to promote podiatry's role in cancer care and improve patient outcomes.
So, should podiatry be a standard part of chemotherapy care? The research suggests it could be a game-changer for many patients. But what do you think? Are we overlooking a simple yet effective solution? Share your thoughts and experiences in the comments below.
